|
When it comes to repealing an obsolete MOU directive and replacing it with robust reporting by pharmacies to state boards of pharmacy – including adverse events reporting by 503As – we will be heard.
And when it comes to protecting patient access to life-enhancing compounded hormone therapy, we will be heard.
Sounds good, right? But here’s the dirty little secret: We need you to help amplify our voice.
To be effective, we must be so loud we can’t be ignored. And we’re only as loud as the number of congressional offices we visit during CCH. And we can only arrange visits with those offices who have a constituent – that’s you – requesting a Capitol Hill meeting.
We’ll do the legwork, scheduling your meeting for you, making sure you’re well briefed. All you have to do is come, and add your voice to those of your compounding colleagues from across the country.
We’re little, but we’re loud. If you join us – get registered and attend CCH – we’ll be a little bigger and a little louder.
With your help, we will be heard.
Read on for more news.
– Scott
Scott Brunner, CAE, is APC’s chief executive officer. Email him at scott@a4pc.org.
| 
